Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan-Dec;15(1):2213793.
doi: 10.1080/19420862.2023.2213793.

Evolution of phage display libraries for therapeutic antibody discovery

Affiliations
Review

Evolution of phage display libraries for therapeutic antibody discovery

Yang Zhang. MAbs. 2023 Jan-Dec.

Abstract

Monoclonal antibodies (mAbs) and their derivatives have emerged as one of the most important classes of biotherapeutics in recent decades. The success of mAb is due to their high versatility, high target specificity, excellent clinical safety profile, and efficacy. Antibody discovery, the most upstream stage of the antibody development pipeline, plays a pivotal role in determination of the clinical outcome of an mAb product. Phage display technology, originally developed for peptide directed evolution, has been extensively applied to discovery of fully human antibodies due to its unprecedented advantages. The value of phage display technology has been proven by a number of approved mAbs, including several top-selling mAb drugs, derived from the technology. Since antibody phage display was first established over 30 years ago, phage display platforms have been developed to generate mAbs targeting difficult-to-target antigens and tackle the drawbacks present in in vivo antibody discovery approaches. More recently, the new generation of phage display libraries have been optimized for discovery of mAbs with "drug-like" properties. This review will summarize the principles of antibody phage display and design of three generations of antibody phage display libraries.

Keywords: Antibody developability; antibody selection; library design; phage display; therapeutic antibody discovery.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author.

Figures

Figure 1.
Figure 1.
Types of antibody phage display libraries (upper left panel), library construction (lower left panel) and antibody selection (right panel). According to source of diversity, antibody phage display libraries can be categorized into three types: natural library, synthetic library, and semisynthetic library. In a typical phagemid system, variable regions of light and heavy chains, either cloned from a natural immunoglobulin repertoire or designed and synthesized in vitro, are cloned into a phage display vector (phagemid), with one of the chains genetically fused to pIII of phage for display. The library pool is then transformed to E.Coli host cells. By infection with helper phage, which provides all the components for phage production, a phage library is generated. Taking solid-phase panning as an example, the phage library is incubated with immobilized antigen. After washing, nonspecific phages are removed and antigen-specific phages stay with the antigen. The bound phages are then dissociated from the antigen by diverse methods, e.g., low-Ph elution, enzymatic cleavage. Lastly, eluted phages are subjected to propagation in E.Coli host cells. After iterative rounds of panning, antigen-specific clones are enriched. Typically, output phages from middle and late rounds of panning are subjected to sequencing and binding characterization for obtaining both sequence diversity and high affinity, respectively.

Similar articles

Cited by

References

    1. Zhu Y, Wang SS, Zhou ZS, Ho M.. The emergence of AntibodyPlus: the future trend of antibody-based therapeutics. Antib Ther. 2022;5:280–17. PMID: 36299417. doi:10.1093/abt/tbac024 - DOI - PMC - PubMed
    1. Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27:1. PMID: 31894001. doi:10.1186/s12929-019-0592-z - DOI - PMC - PubMed
    1. Strohl WR. Current progress in innovative engineered antibodies. Protein Cell. 2018;9:86–120. PMID: 28822103. doi:10.1007/s13238-017-0457-8 - DOI - PMC - PubMed
    1. Roth KDR, Wenzel EV, Ruschig M, Steinke S, Langreder N, Heine PA, Schneider KT, Ballmann R, Fuhner V, Kuhn P, et al. Developing recombinant antibodies by phage display against infectious diseases and toxins for diagnostics and therapy. Front Cell Infect Microbiol. 2021;11:697876. PMID: 34307196. doi:10.3389/fcimb.2021.697876. - DOI - PMC - PubMed
    1. Nagano K, Tsutsumi Y. Phage display technology as a powerful platform for antibody drug discovery. Viruses. 2021;13(2):178. PMID: 33504115. doi:10.3390/v13020178. - DOI - PMC - PubMed

Substances

LinkOut - more resources